Monitoring drug safety with registries: Useful components of postmarketing pharmacovigilance systems

Journal of Clinical Epidemiology

Volumn 65, Issue 2, 2012, Pages 121-125

  Willis, Cameron D ^a   McNeil, John J ^b   Cameron, Peter A ^b   Phillips, Louise E ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Adverse drug reaction reporting systems; Postmarketing; Product surveillance; Registries; Safety; Safety management

Indexed keywords

BOSENTAN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCINE; HUMAN SERUM ALBUMIN; LAMOTRIGINE; POLYSORBATE 80; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; TUMOR NECROSIS FACTOR ANTIBODY;

ADVERSE DRUG REACTION; ARTICLE; AUSTRALIAN RHEUMATOLOGY ASSOCIATION DATABASE; BLEEDING; BOSENTAN PATIENT REGISTRY; BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGIC REGISTER; CHRONIC KIDNEY FAILURE; CONGENITAL MALFORMATION; DRUG COST; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS REGISTRY; HUMAN; INFECTION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE IMMUNOGENICITY SURVEILLANCE REGISTRY; PULMONARY HYPERTENSION; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RHEUMATOID ARTHRITIS; SEIZURE; TERATOGENICITY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 84855343529     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2011.06.017     Document Type: Note

References (28)

1. World Health Organisation Collaborating Centre for International Drug Monitoring. The importance of pharmacovigilance: safety and monitoring of medicinal products. Uppsala: WHO; 2002. Contract no.: ISBN 9241590157.
2. Bresalier R, Sandler R, Quan H, Bolognese J, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005;352:1092-102. (Pubitemid 40365350)
3. Aagaard L, Holme Hansen E. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clin Pharmacol 2009;9:4.
4. Ray W. Population-based studies of adverse drug effects. New Engl J Med 2003;349:1592-4. (Pubitemid 37288566)
5. Hrmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.
6. Luo X, Cappelleri J, Frush K. A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics. Curr Med Res Opin 2007;23:1015-24. (Pubitemid 46799583)
7. Waller P, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003;12:17-29. (Pubitemid 36192946)
8. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006;24:613-4. (Pubitemid 43884419)
9. Sharma B, Ryan M, Boven K. Reactions to Eprex's adverse reactions. Nat Biotechnol 2006;24:1199-200. [author reply 1200].
10. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005 Apr;58:323-37. (Pubitemid 40601980)
11. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol 2011;64:424-30.
12. Hyrich KL, Watson KD, Isenberg DA, Symmons DPM. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
13. Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, et al. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern Med J 2007;37:591-600. (Pubitemid 47262900)
14. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8. (Pubitemid 36277997)
15. Carr M, Martin E. Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Expert Rev Cardiovasc Ther 2004;2:661-74. (Pubitemid 39255531)
16. Willis C, Bird R, Mullany D, Cameron P, Phillips L. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 2010;98:531-7.
17. Willis CD, Cameron PA, Phillips L. Variation in the use of recombinant activated factor VII in critical bleeding. Intern Med J 2010;40:486-93.
18. Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 2010;38:671-7.
19. Willis CD, Jolley DJ, McNeil JJ, Cameron PA, Phillips LE. Identifying and improving unreliable items in registries through data auditing. Int J Qual Health Care 2011;23:317-23.
20. Colvin L, Slack-Smith L, Stanley F, Bower C. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 2009;18:211-25.
21. Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Moral Educ 2008;11:235-43.
22. Department of Health and Ageing. December 2003 PBAC outcomes - positive recommendations. Canberra: Pharmaceutical Benefits Scheme, Commonwealth of Australia; 2004.
23. GlaxoSmithKline. The Lamotrigine Pregnancy Registry interim report: 1 September 1992 through 31 March 2007. Wilmington, NC: 2007.
24. Cunnington M. The International Lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 2004;45:1468. (Pubitemid 39470057)
25. Briggs G, Polifka J. Better data needed from pregnancy registries. Birth Defects Research Part A. Clin Mol Teratol 2009;85: 109-11.
26. Australian Commission on Safety and Quality in Healthcare. Operating principles and technical standards for Australian clinical quality registries. Canberra: Australian Commission on Safety and Quality in Healthcare; 2008. Contract no: TRIM Record 20308.
27. Kremer J, Gibofsky A, Greenberg J. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008;20:123-30. (Pubitemid 351339882)
28. O'Connor R, Gilmore A, Manjunath R, Stanford R, Legorreta A, Jhingran P. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives. Curr Med Res Opin 2006;22:453-61.